Please assess the completion status of the following clinical trial:

Trial Title: GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Provision of a written informed consent~* Men or women who are 30 to 80 years of age~* Female patients: postmenopausal or surgically sterile~* Diagnosed with type 2 diabetes with C-peptide levels \> 0.8 ng/mL~* Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents~Exclusion Criteria:~* Type 1 diabetes~* New York Heart Association heart failure Class III or IV~* Treatment with chronic insulin~* History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), or to other PPAR g or PPAR a and g agonists.~* History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)~* Creatinine levels above 1.2 mg/dL~* Received any investigational product in other clinical studies within 30 days~* Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).